Source: American journal of medical genetics part a. Unidade: FM
ABNT
BALDI, Bruno Guedes et al. COVID-19 and lymphangioleiomyomatosis.. [Carta]: experience at a reference center and the potential impact of the use ofmTORinhibitors. American journal of medical genetics part a. Hoboken: Faculdade de Medicina, Universidade de São Paulo. Disponível em: https://doi.org/10.1002/ajmg.a.61877. Acesso em: 12 set. 2024. , 2020APA
Baldi, B. G., Amaral, A. F., Colares, P. de F. B., Kairalla, R. A., Oliveira, M. R. de, & Carvalho, C. R. R. D. (2020). COVID-19 and lymphangioleiomyomatosis.. [Carta]: experience at a reference center and the potential impact of the use ofmTORinhibitors. American journal of medical genetics part a. Hoboken: Faculdade de Medicina, Universidade de São Paulo. doi:10.1002/ajmg.a.61877NLM
Baldi BG, Amaral AF, Colares P de FB, Kairalla RA, Oliveira MR de, Carvalho CRRD. COVID-19 and lymphangioleiomyomatosis.. [Carta]: experience at a reference center and the potential impact of the use ofmTORinhibitors [Internet]. American journal of medical genetics part a. 2020 ; 182( 12): 3068-3070.[citado 2024 set. 12 ] Available from: https://doi.org/10.1002/ajmg.a.61877Vancouver
Baldi BG, Amaral AF, Colares P de FB, Kairalla RA, Oliveira MR de, Carvalho CRRD. COVID-19 and lymphangioleiomyomatosis.. [Carta]: experience at a reference center and the potential impact of the use ofmTORinhibitors [Internet]. American journal of medical genetics part a. 2020 ; 182( 12): 3068-3070.[citado 2024 set. 12 ] Available from: https://doi.org/10.1002/ajmg.a.61877